Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?
Purpose of Review Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatme...
Gespeichert in:
| Veröffentlicht in: | Current infectious disease reports 2024-05, Vol.26 (5), p.139-150 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 150 |
|---|---|
| container_issue | 5 |
| container_start_page | 139 |
| container_title | Current infectious disease reports |
| container_volume | 26 |
| creator | Mangum, Blake R. Pogue, Jason M. Barber, Katie E. |
| description | Purpose of Review
Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.
Recent Findings
To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.
Summary
Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing. |
| doi_str_mv | 10.1007/s11908-024-00831-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3061538148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3061538148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-2f8670aae5bdaa80e65e74603db0e370a8fd3fabc223ce3a104062384f3ef5413</originalsourceid><addsrcrecordid>eNp9UEtPwzAMjhBIjMEf4BSJc8CJ0zZwQWgbD2kSB8Y5SlsHbdqakayH_XuyFYkbJ9vy97A_xq4l3EqA6i5JeQ9GgNICwKAU8oSNZIFaoNTl6aFXKNDo6pxdpLQCUJlmRqxaUL3cUkcb7rqWf_TrcJwe-HTfuc2y4dM-8BD5NPT1mvgiHuvjJTvzbp3o6reO2efzbDF5FfP3l7fJ01w02XgnlDdlBc5RUbfOGaCyoEqXgG0NhHljfIve1Y1S2BA6CRpKle_0SL7QEsfsZtDdxvDdU9rZVehjly0tQpk_NFKbjFIDqokhpUjebuNy4-LeSrCHgOwQkM0B2WNA9iCNAyllcPdF8U_6H9YPhXpm2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3061538148</pqid></control><display><type>article</type><title>Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?</title><source>Springer Nature - Complete Springer Journals</source><creator>Mangum, Blake R. ; Pogue, Jason M. ; Barber, Katie E.</creator><creatorcontrib>Mangum, Blake R. ; Pogue, Jason M. ; Barber, Katie E.</creatorcontrib><description>Purpose of Review
Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.
Recent Findings
To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.
Summary
Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.</description><identifier>ISSN: 1523-3847</identifier><identifier>EISSN: 1534-3146</identifier><identifier>DOI: 10.1007/s11908-024-00831-1</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibiotic resistance ; Antimicrobial Development and Drug Resistance (KC Claeys and J Smith ; Bioavailability ; Gastrointestinal tract ; Infectious Diseases ; Medicine ; Medicine & Public Health ; Mortality ; Public health ; Section Editors ; Topical Collection on Antimicrobial Development and Drug Resistance ; Urinary tract infections</subject><ispartof>Current infectious disease reports, 2024-05, Vol.26 (5), p.139-150</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c314t-2f8670aae5bdaa80e65e74603db0e370a8fd3fabc223ce3a104062384f3ef5413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11908-024-00831-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11908-024-00831-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Mangum, Blake R.</creatorcontrib><creatorcontrib>Pogue, Jason M.</creatorcontrib><creatorcontrib>Barber, Katie E.</creatorcontrib><title>Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?</title><title>Current infectious disease reports</title><addtitle>Curr Infect Dis Rep</addtitle><description>Purpose of Review
Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.
Recent Findings
To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.
Summary
Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.</description><subject>Antibiotic resistance</subject><subject>Antimicrobial Development and Drug Resistance (KC Claeys and J Smith</subject><subject>Bioavailability</subject><subject>Gastrointestinal tract</subject><subject>Infectious Diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Public health</subject><subject>Section Editors</subject><subject>Topical Collection on Antimicrobial Development and Drug Resistance</subject><subject>Urinary tract infections</subject><issn>1523-3847</issn><issn>1534-3146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9UEtPwzAMjhBIjMEf4BSJc8CJ0zZwQWgbD2kSB8Y5SlsHbdqakayH_XuyFYkbJ9vy97A_xq4l3EqA6i5JeQ9GgNICwKAU8oSNZIFaoNTl6aFXKNDo6pxdpLQCUJlmRqxaUL3cUkcb7rqWf_TrcJwe-HTfuc2y4dM-8BD5NPT1mvgiHuvjJTvzbp3o6reO2efzbDF5FfP3l7fJ01w02XgnlDdlBc5RUbfOGaCyoEqXgG0NhHljfIve1Y1S2BA6CRpKle_0SL7QEsfsZtDdxvDdU9rZVehjly0tQpk_NFKbjFIDqokhpUjebuNy4-LeSrCHgOwQkM0B2WNA9iCNAyllcPdF8U_6H9YPhXpm2A</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Mangum, Blake R.</creator><creator>Pogue, Jason M.</creator><creator>Barber, Katie E.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20240501</creationdate><title>Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?</title><author>Mangum, Blake R. ; Pogue, Jason M. ; Barber, Katie E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-2f8670aae5bdaa80e65e74603db0e370a8fd3fabc223ce3a104062384f3ef5413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibiotic resistance</topic><topic>Antimicrobial Development and Drug Resistance (KC Claeys and J Smith</topic><topic>Bioavailability</topic><topic>Gastrointestinal tract</topic><topic>Infectious Diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Public health</topic><topic>Section Editors</topic><topic>Topical Collection on Antimicrobial Development and Drug Resistance</topic><topic>Urinary tract infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mangum, Blake R.</creatorcontrib><creatorcontrib>Pogue, Jason M.</creatorcontrib><creatorcontrib>Barber, Katie E.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Current infectious disease reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mangum, Blake R.</au><au>Pogue, Jason M.</au><au>Barber, Katie E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?</atitle><jtitle>Current infectious disease reports</jtitle><stitle>Curr Infect Dis Rep</stitle><date>2024-05-01</date><risdate>2024</risdate><volume>26</volume><issue>5</issue><spage>139</spage><epage>150</epage><pages>139-150</pages><issn>1523-3847</issn><eissn>1534-3146</eissn><abstract>Purpose of Review
Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.
Recent Findings
To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.
Summary
Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11908-024-00831-1</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3847 |
| ispartof | Current infectious disease reports, 2024-05, Vol.26 (5), p.139-150 |
| issn | 1523-3847 1534-3146 |
| language | eng |
| recordid | cdi_proquest_journals_3061538148 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Antibiotic resistance Antimicrobial Development and Drug Resistance (KC Claeys and J Smith Bioavailability Gastrointestinal tract Infectious Diseases Medicine Medicine & Public Health Mortality Public health Section Editors Topical Collection on Antimicrobial Development and Drug Resistance Urinary tract infections |
| title | Tebipenem and Sulopenem: Dynamic Duo or Double Trouble? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T19%3A52%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tebipenem%20and%20Sulopenem:%20Dynamic%20Duo%20or%20Double%20Trouble?&rft.jtitle=Current%20infectious%20disease%20reports&rft.au=Mangum,%20Blake%20R.&rft.date=2024-05-01&rft.volume=26&rft.issue=5&rft.spage=139&rft.epage=150&rft.pages=139-150&rft.issn=1523-3847&rft.eissn=1534-3146&rft_id=info:doi/10.1007/s11908-024-00831-1&rft_dat=%3Cproquest_cross%3E3061538148%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3061538148&rft_id=info:pmid/&rfr_iscdi=true |